00:48 , Aug 2, 2019 |  BC Extra  |  Clinical News

Amicus’ Batten disease gene therapy shows preserved speech, motor function

Interim data for Amicus’ most advanced Batten disease gene therapy suggest that the biotech’s recent addition of the modality to its pipeline could be paying off. On Thursday, Amicus reported interim Phase I/II data showing...
21:53 , May 29, 2019 |  BC Extra  |  Company News

Amicus bolsters rare disease gene therapy pipeline with expanded UPenn deal

Amicus has added three more rare disease gene therapy programs to its pipeline through an expansion of its deal with the University of Pennsylvania, with the option to add at least a dozen more. The...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
16:34 , Sep 21, 2018 |  BC Week In Review  |  Company News

Celenex takeout first of several expected Amicus gene therapy deals

Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million...
23:14 , Sep 20, 2018 |  BC Extra  |  Company News

Celenex takeout first of several planned gene therapy deals for Amicus

Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million...